PDS Biotechnology Corp - Common (PDSB)

CUSIP: 70465T107

Q3 2019 13F Holders as of 30 Sep 2019

Type / Class
Equity / Common
Shares outstanding
49,594,356
Total 13F shares
509,321
Share change
+47,985
Total reported value
$1,716,054
Price per share
$3.37
Number of holders
16
Value change
+$122,431
Number of buys
7
Number of sells
4

Security key

70465T107

Report period

Q3 2019

Institutions

16

Top holders

10

Top shareholders of PDSB - PDS Biotechnology Corp - Common (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Sofinnova Investments, Inc.
13F
Company
0.29%
142,635
$854,000 30 Jun 2019
13F
New Leaf Venture Partners, L.L.C.
13F
Company
0.24%
117,242
$702,000 30 Jun 2019
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
0.16%
78,469
$470,000 30 Jun 2019
13F
VANGUARD GROUP INC
13F
Company
0.04%
21,986
$132,000 30 Jun 2019
13F
INSPIRION WEALTH ADVISORS, LLC
13F
Company
0.04%
21,350
$128,000 30 Jun 2019
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.04%
18,136
$108,000 30 Jun 2019
13F
DIMENSIONAL FUND ADVISORS LP
13F
Company
0.03%
14,516
$87,000 30 Jun 2019
13F
BlackRock Finance, Inc.
13F
Company
0.03%
14,413
$87,000 30 Jun 2019
13F
D. E. Shaw & Co., Inc.
13F
Company
0.03%
13,678
$82,000 30 Jun 2019
13F
Samsara BioCapital, LLC
13F
Company
0.02%
9,166
$55,000 30 Jun 2019
13F
PANAGORA ASSET MANAGEMENT INC
13F
Company
0.01%
3,932
$24,000 30 Jun 2019
13F
Ellis Investment Partners, LLC
13F
Company
0.01%
3,250
$19,000 30 Jun 2019
13F
UBS Group AG
13F
Company
0%
1,583
$9,000 30 Jun 2019
13F
ROYAL BANK OF CANADA
13F
Company
0%
360
$2,000 30 Jun 2019
13F
PNC FINANCIAL SERVICES GROUP, INC.
13F
Company
0%
300
$2,000 30 Jun 2019
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
104
$1,000 30 Jun 2019
13F
BNP PARIBAS FINANCIAL MARKETS
13F
Company
0%
16
$96 30 Jun 2019
13F

Institutional Holders of PDS Biotechnology Corp - Common (PDSB) as of Q3 2019

As of 30 Sep 2019, PDS Biotechnology Corp - Common (PDSB) was held by 16 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 509,321 shares. The largest 10 holders included Sofinnova Investments, Inc., New Leaf Venture Partners, L.L.C., RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, INSPIRION WEALTH ADVISORS, LLC, REGENTATLANTIC CAPITAL LLC, GEODE CAPITAL MANAGEMENT, LLC, AMUSSEN HUNSAKER ASSOCIATES LLC, DIMENSIONAL FUND ADVISORS LP, and BlackRock Inc.. This page lists 16 institutional shareholders reporting positions in this security for the Q3 2019 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q3 2019 vs Q2 2019 Across Filers

Q2 2019 holders
16
Q3 2019 holders
16
Holder diff
0
Investor Q2 2019 Shares Q3 2019 Shares Share Diff Share Chg % Q2 2019 Value $ Q3 2019 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .